Product
Adavosertib
Aliases
adavosertib 20 mg, adavosertib 65 mg, MK-1775
4 clinical trials
4 indications
Indication
Cervical CancerIndication
Advanced Solid TumoursIndication
Solid TumorsIndication
Uterine Serous CarcinomaClinical trial
A Two Part, Phase I-IIa Study Evaluating MK1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical CancerStatus: Terminated, Estimated PCD: 2011-06-13
Clinical trial
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor), Rifampicin (a CYP3A4 Inducer), and Omeprazole (a Proton Pump Inhibitor) on the Pharmacokinetics of a Single Oral Dose of Adavosertib in Patients With Advanced Solid TumoursStatus: Terminated, Estimated PCD: 2022-06-01
Clinical trial
A Phase I Dose Escalation Study of MK1775 in Monotherapy, in Combination With 5-Fluorouracil, and in Combination With 5-Fluorouracil and Cisplatin in Patients With Advanced Solid TumorStatus: Terminated, Estimated PCD: 2011-06-15
Clinical trial
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous CarcinomaStatus: Completed, Estimated PCD: 2022-05-23